| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/28/2013 | WO2013044176A2 Methods and compositions for the treatment of ischemic stroke |
| 03/28/2013 | WO2013044123A1 Uses of bis(3)-cognitin and related compounds |
| 03/28/2013 | WO2013044119A1 Compositions and methods related to deoxycholic acid and its polymorphs |
| 03/28/2013 | WO2013044111A1 Compositions for skin exfoliation and use thereof |
| 03/28/2013 | WO2013044092A1 Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| 03/28/2013 | WO2013044058A1 Mitochondria-targeted antioxidants for treatment of age-related brain disorders |
| 03/28/2013 | WO2013044044A2 Methods of treating fatty liver disease with helminth-derived glycan-containing compounds |
| 03/28/2013 | WO2013044028A2 Mycophenolic acid analogues as anti-tumor chemosensitizing agents |
| 03/28/2013 | WO2013043985A1 Edible oils to enhance delivery of orally administered steroids |
| 03/28/2013 | WO2013043967A1 Romidepsin and 5 - azacitidine for use in treating lymphoma |
| 03/28/2013 | WO2013043964A1 Acyclic cyanoethylpyrazoles as janus kinase inhibitors |
| 03/28/2013 | WO2013043962A1 Cyanomethylpyrazole carboxamides as janus kinase inhibitors |
| 03/28/2013 | WO2013043961A1 Compounds useful as inhibitors of choline kinase |
| 03/28/2013 | WO2013043960A1 Compounds useful as inhibitors of choline kinase |
| 03/28/2013 | WO2013043925A1 Sodium channel blockers reduce glucagon secretion |
| 03/28/2013 | WO2013043866A1 Nicotine-containing pharmaceutical composition |
| 03/28/2013 | WO2013043840A1 Method for treating osteoporosis |
| 03/28/2013 | WO2013043839A1 Biosensor with error compensation |
| 03/28/2013 | WO2013043826A1 Tricyclic compounds useful as protein kinase inhibitors |
| 03/28/2013 | WO2013043778A1 Novel betulinic acid derivatives with antiviral activity |
| 03/28/2013 | WO2013043744A2 Tricyclic compounds useful as neurogenic and neuroprotective agents |
| 03/28/2013 | WO2013043719A1 Controlling appetite, promoting weight loss, reducing body fat, and/or improving glucose tolerance |
| 03/28/2013 | WO2013043715A1 Combination treatments comprising c-met antagonists and b-raf antagonists |
| 03/28/2013 | WO2013043637A1 Method and composition for treating pain |
| 03/28/2013 | WO2013043624A1 Substituted pyrimidines |
| 03/28/2013 | WO2013043621A1 Substituted pyrimidines |
| 03/28/2013 | WO2013043580A2 Modified creatine compounds |
| 03/28/2013 | WO2013043569A1 Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| 03/28/2013 | WO2013043558A1 Compositions and methods for treating cancer |
| 03/28/2013 | WO2013043529A1 Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto |
| 03/28/2013 | WO2013043387A1 Ophthalmic gel compositions |
| 03/28/2013 | WO2013043304A1 Estrogen receptor ligands and methods of use thereof |
| 03/28/2013 | WO2013043255A1 Methods and compositions for the treatment of ovarian cancer |
| 03/28/2013 | WO2013043236A1 Compositions and methods useful for realtime in situ physiological molecular imaging of oxygen metabolism |
| 03/28/2013 | WO2013043232A2 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h) -ones for the treatment of nervous system disorders and cancer |
| 03/28/2013 | WO2013043193A1 Methods and compositions for reducing symptoms associated with physiological stress |
| 03/28/2013 | WO2013043192A1 Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders |
| 03/28/2013 | WO2013043142A1 Production method for pharmaceutical formulations comprising an isoflavone |
| 03/28/2013 | WO2013043115A1 Method of increasing cell proliferation by advanced wound dressings |
| 03/28/2013 | WO2013043085A1 Pharmaceutical substance (variants) and compositions based thereon which exhibit modulatory activity with a commensurate effect |
| 03/28/2013 | WO2013043064A1 Veterinary anthelmintic delivery system |
| 03/28/2013 | WO2013043028A1 Composition for skin premature ageing prevention |
| 03/28/2013 | WO2013043002A1 Imide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same |
| 03/28/2013 | WO2013043001A1 Phenylimide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same |
| 03/28/2013 | WO2013042989A1 Percutaneously absorbable preparation containing fentanyl and a homologue thereof |
| 03/28/2013 | WO2013042782A1 Condensed heterocyclic compound |
| 03/28/2013 | WO2013042378A1 Deodorant composition |
| 03/28/2013 | WO2013042140A2 Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement |
| 03/28/2013 | WO2013042139A1 Amide compounds, compositions and applications thereof |
| 03/28/2013 | WO2013042137A1 Bicyclic heterocycles as irak4 inhibitors |
| 03/28/2013 | WO2013042135A1 Heteroaryl compounds as 5-ht4 receptor ligands |
| 03/28/2013 | WO2013042124A1 Use of strigolactones and strigolactone analogs for treating proliferative conditions |
| 03/28/2013 | WO2013042122A1 Beta-lactam compounds for enhancing t cell -mediated immune responses |
| 03/28/2013 | WO2013042121A1 Beta-lactam compounds for treating diabetes |
| 03/28/2013 | WO2013042082A1 Novel compounds modulating the hedgehog protein signaling pathway, marked forms thereof, and applications |
| 03/28/2013 | WO2013042077A1 Diagnosis of tuberculosis |
| 03/28/2013 | WO2013042067A1 Process for the preparation of potassium salt of azilsartan medoxomil |
| 03/28/2013 | WO2013042066A1 Process for the preparation of azilsartan medoxomil |
| 03/28/2013 | WO2013042065A2 Inhibitors of type ii ribosome inactivating proteins |
| 03/28/2013 | WO2013042006A1 Pyrrolopyrimidine and purine derivatives |
| 03/28/2013 | WO2013042005A1 N- substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders |
| 03/28/2013 | WO2013041967A2 Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
| 03/28/2013 | WO2013041963A2 A composition and method for treating an autoimmune disease |
| 03/28/2013 | WO2013041944A1 Process for the preparation of micronized candesartan cilexetil |
| 03/28/2013 | WO2013041895A1 Novel medicinal compounds |
| 03/28/2013 | WO2013041859A1 Cannabinoid-2-receptor agonists |
| 03/28/2013 | WO2013041851A1 New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
| 03/28/2013 | WO2013041810A1 Stable, low-toxicity, sterilizable composition for ophthalmic dying |
| 03/28/2013 | WO2013041732A1 Total synthesis and immunological evaluation of saccharide moieties of the lipopolysaccharide from neisseria meningitidis |
| 03/28/2013 | WO2013041696A1 Stimulating and invigorating nasal spray and nasal drop |
| 03/28/2013 | WO2013041652A1 Morpholino substituted urea or carbamate derivatives as mtor inhibitors |
| 03/28/2013 | WO2013041634A1 Substituted imidazopyridazines |
| 03/28/2013 | WO2013041621A1 Low molecular weight modulators of the cold-menthol receptor trpm8 and use thereof |
| 03/28/2013 | WO2013041606A1 Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
| 03/28/2013 | WO2013041605A1 Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors |
| 03/28/2013 | WO2013041604A1 Crystal form of asenapine maleate |
| 03/28/2013 | WO2013041591A1 New bicyclic dihydroquinoline-2-one derivatives |
| 03/28/2013 | WO2013041542A1 Pharmaceutical formulations comprising spherolyophilisates of biological molecules |
| 03/28/2013 | WO2013041539A1 Imidazopyridine compounds, compositions and methods of use |
| 03/28/2013 | WO2013041537A1 Heterocyclocarbonylaminothiazoles, cosmetic or dermatological preparations containing said heterocyclocarbonylaminothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin |
| 03/28/2013 | WO2013041535A1 Aromatic amidothiazoles, cosmetic or dermatological preparations containing said aromatic amidothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin |
| 03/28/2013 | WO2013041526A1 Alkylamidothiazoles, cosmetic or dermatological preparations containing said alkylamidothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin |
| 03/28/2013 | WO2013041519A1 Ror gamma modulators |
| 03/28/2013 | WO2013041502A1 N-[4-(1h-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals |
| 03/28/2013 | WO2013041499A1 N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors |
| 03/28/2013 | WO2013041497A1 Substituted n- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin c |
| 03/28/2013 | WO2013041480A1 New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments |
| 03/28/2013 | WO2013041472A1 Triazolopyridine compounds as pde10a inhibitors |
| 03/28/2013 | WO2013041468A1 Benzoic acid derivatives as eif4e inhibitors |
| 03/28/2013 | WO2013041461A1 Fsh receptor antagonists |
| 03/28/2013 | WO2013041458A1 Fsh receptor antagonists |
| 03/28/2013 | WO2013041457A1 N-piperidin-4-yl derivatives |
| 03/28/2013 | WO2013041435A1 Compressed oral dosage form for asenapine maleate |
| 03/28/2013 | WO2013041407A1 Hydroxamic acids as hdac6 inhibitors |
| 03/28/2013 | WO2013041238A1 Use of kibra peptides, hdac inhibitor or proteasome inhibitor for improving anxiety disorders |
| 03/28/2013 | WO2013041206A1 Pharmaceutical combination drug |
| 03/28/2013 | WO2013041205A1 Novel therapeutic concepts for treating vascular diseases |
| 03/28/2013 | WO2013041204A1 Novel isocyanate and isothiocyanate compounds for cancer treatment |
| 03/28/2013 | WO2013041119A1 N-[4-(1h-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals |
| 03/28/2013 | WO2013041042A1 Pyrazole carboxamides as janus kinase inhibitors |